title: [Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study].
abstract: Intermittent claudication can seriously impair the patients' quality of life. Cilostazol was registered in Hungary in 2014. This study aimed to evaluate the efficacy and safety of cilostazol in patients with intermittent claudication. 1405 patients were enrolled to the 6 months, multicenter, non-interventional trial. From the 1331 patients, who completed the study, the data of 674 patients were subjected to efficacy analysis. Pain free and maximal walking distance and the 6 minute walking test improved significantly at 3 months (78.65%, 65.23%, 56.09%; respectively, p<0.001), and a further increase was observed after 6 months treatment (129.74%, 107.2, 80.38% respectively, p<0.001). Adverse events occured in 7.26% of the patients. The most frequent adverse events were headache, diarrhea, dizziness, tachycardia or palpitation. 24 patients (1.7%) stopped cilostazol treatment because of side effects. 6 month cilostazol treatment significantly increased the walking distance in patients with intermittent claudication, without important safety problems. Orv. Hetil., 2017, 158(4), 123-128.
authors.affiliation: Angiológia, Szent Imre Egyetemi Oktató Kórház Budapest, Tétényi út 12-16., 1115.
authors.forename: Katalin
authors.initials: K
authors.lastname: Farkas
authors.affiliation: Kardiológia, Szent Imre Egyetemi Oktató Kórház Budapest.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Járai
authors.affiliation: Angiológia, Szent Imre Egyetemi Oktató Kórház Budapest, Tétényi út 12-16., 1115.
authors.forename: Endre
authors.initials: E
authors.lastname: Kolossváry
mesh_terms: D000077407:Cilostazol; D005080:Exercise Test; D005260:Female; D006801:Humans; D006814:Hungary; D007383:Intermittent Claudication / Q000188:drug therapy*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016138:Walking
chemical_list: D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol
keywords: cilostazol; claudicatio intermittens; intermittent claudication; perifériás verőérbetegség; peripheral arterial disease